Tobira (TBRA) Large Shareholder Pentwater Buys, Not Sells Following Allergan Deal
- Dow set to open at record high; oil hits $55
- Oil tops $55 for first time in 16 months as OPEC deal fuels buying
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Wall St. stock futures fall after Italy referendum
- Burberry rejects multiple takeover offers from Coach: Financial Times
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
In an interestingly development, large Tobira Therapeutics (NASDAQ: TBRA) shareholder Pentwater Capital did not cash out following the 733% surge in the stock after the acquisition announcement by Allergan (NYSE: AGN). Instead, the firm has added to its position.
The group bought 1,624,200 shares from 09/20-09/22 at prices from $38.87-$39.45, which brings their stake to 3,533,200 shares. Tobira shares closed today at $39.50.
On Tuesday (09/20), Tobira Therapeutics agreed to be acquired for an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestone.
It is clear, Pentwater Capital sees value in the CVR's.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: BAT Said to Plan Increased Bid for Reynolds American (RAI) as Soon as This Week - Bloomberg
- Pandora (P) Advisers Said to Begin Reaching Out to Possible Suitors Following Approach from Sirius (SIRI) - Bloomberg
- Exclusive: U.S. networking company Ixia explores sale - sources
Create E-mail Alert Related Categories13Gs, Hedge Funds, Insider Trades, Mergers and Acquisitions, Rumors, Trader Talk
Related EntitiesPentwater Capital, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!